Dashboard
Financial statements
INCY

Company financials

Incyte

Health Care Biotechnology Wilmington, Delaware Last filing Feb 10, 2026 · FY2025
Revenue FY2025
$5.1B
3y CAGR +14.8% P90
Net income FY2025
$1.3B
Net margin +25.0% P84
Total assets FY2025
$7.0B
ROA +18.5% P96
Operating cash flow FY2025
$1.4B
FCF margin +26.3% P90
17 yrs · FY2009–FY2025 9 filed · 0 derived · 0 blank

Running CAGR since the earliest displayed year.

Balance Sheet

Assets, liabilities, and equity

26 accounts · 1 year
Total assets $7.0B
Total liabilities $1.8B
Shareholders equity $5.2B
Account 2025 Trend
Assets
Cash and Cash Equivalents —
Short Term Investments —
Accounts Receivable —
Inventory —
Prepaid Expenses —
Total Current Assets —
Property,Plant and Equipment —
Goodwill —
Intangible Assets —
Deferred Tax Assets —
Other Noncurrent Assets —
Total Assets —
Liabilities
Accounts Payable —
Accrued Liabilities —
Other Current Liabilities —
Total Current Liabilities —
Operating Lease Liabilities Noncurrent —
Other Noncurrent Liabilities —
Total Liabilities —
Equity
Preferred Stock —
Common Stock —
Additional Paid In Capital —
Retained Earnings —
Accumulated Other Comprehensive Income —
Total Stockholders Equity —
Total Liabilitiesand Equity —

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year
Ratio 2025
Profitability
Gross margin +92.8%
Operating margin +29.5%
Net margin +25.0%
FCF margin +26.3%
Growth
Revenue CAGR (3y) +14.8%
Returns
ROE +24.9%
ROA +18.5%
ROIC —
Liquidity
Current ratio 3.32x
Quick ratio 2.72x
Leverage
D/E 0.35x
Interest coverage 623.91x
Efficiency
Asset turnover 0.74x
Cash conversion cycle -34d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched
Saving notes adds INCY to your watchlist.